The Oncology Care Model (OCM) is a new payment and delivery model designed to improve the effectiveness and efficiency of oncology care and aims to provide higher quality, better coordinated oncology care. On July 1, 2016, the Center for Medicare & Medicaid Innovation launched the OCM within 195 oncology clinics across the US. Under this multi-payer model physician practices enter into payment arrangements that provide financial incentives based on performance accountability for episodes of care surrounding chemotherapy administration to cancer patients. The practices participating in OCM have committed to providing enhanced services to Medicare beneficiaries such as care coordination, navigation, and integration of evidence-based care and national treatment guidelines.

Despite including Medicare Fee-For-Service, the Oncology Care Model is facilitating the transition to valuebased care accountability as the standard in oncology care. For those oncology clinics not included in the 195 clinics piloting the OCM, the focus on value and quality continue with payment models and requirements under MACRA.

MEDX|Oncology is a 2-day, multi-topic CME/CPE/CNE conference designed for the oncology care team including physicians, nurse practitioners, physician assistants, registered nurses, nurse navigators, and pharmacists who work in an oncology practice setting.

MEDX|Oncology conference have been developed to provide oncology treatment teams with practice and system-based strategies to narrow the widening gap between evidence-based treatment recommendations, current practice patterns, and reimbursement requirements.

CONFERENCE LEARNING OBJECTIVES
At the conclusion of this 2-day conference, participants should be able to demonstrate the ability to:

1. Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
2. Evaluate the sequential and combination administration of chemotherapy and targeted agents to optimize patient survival
3. Discuss current recommendations for diagnostic testing across multiple tumor types to facilitate treatment selection
4. Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of multiple tumor types with attention to cost/benefit and toxicity considerations
5. Employ communication strategies and resources to increase patient access and engagement